Huaren Pharmaceutical Co., Ltd. (300110.SZ)
CNY 2.9
(3.2%)
CNY 2.9
(3.2%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 225.94 Million CNY | 13.83% |
| 2022 | 198.49 Million CNY | 31.19% |
| 2021 | 151.3 Million CNY | 32.67% |
| 2020 | 114.04 Million CNY | 54.03% |
| 2019 | 74.04 Million CNY | 54.93% |
| 2018 | 47.78 Million CNY | -25.12% |
| 2017 | 63.82 Million CNY | 97.98% |
| 2016 | 32.23 Million CNY | 42.3% |
| 2015 | 22.65 Million CNY | -65.18% |
| 2014 | 65.06 Million CNY | -54.44% |
| 2013 | 142.81 Million CNY | 26.79% |
| 2012 | 112.63 Million CNY | 18.27% |
| 2011 | 95.24 Million CNY | 13.28% |
| 2010 | 84.07 Million CNY | 12.42% |
| 2009 | 74.78 Million CNY | 37.75% |
| 2008 | 54.29 Million CNY | 47.68% |
| 2007 | 36.76 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 29.67 Million CNY | -58.51% |
| 2024 Q3 | 39.82 Million CNY | 34.21% |
| 2024 Q1 | 71.5 Million CNY | 0.44% |
| 2023 Q3 | 66.31 Million CNY | 58.81% |
| 2023 Q4 | 71.19 Million CNY | 7.36% |
| 2023 FY | 225.94 Million CNY | 13.83% |
| 2023 Q1 | 46.67 Million CNY | -12.92% |
| 2023 Q2 | 41.75 Million CNY | -10.55% |
| 2022 FY | 198.49 Million CNY | 31.19% |
| 2022 Q2 | 59.74 Million CNY | 80.46% |
| 2022 Q3 | 52.03 Million CNY | -12.91% |
| 2022 Q4 | 53.6 Million CNY | 3.03% |
| 2022 Q1 | 33.1 Million CNY | 2186.4% |
| 2021 Q3 | 62.63 Million CNY | 15.71% |
| 2021 FY | 151.3 Million CNY | 32.67% |
| 2021 Q1 | 33.08 Million CNY | -29.91% |
| 2021 Q2 | 54.13 Million CNY | 63.61% |
| 2021 Q4 | 1.44 Million CNY | -97.69% |
| 2020 FY | 114.04 Million CNY | 54.03% |
| 2020 Q3 | 23.43 Million CNY | -33.55% |
| 2020 Q4 | 47.2 Million CNY | 101.41% |
| 2020 Q1 | 8.12 Million CNY | -75.05% |
| 2020 Q2 | 35.27 Million CNY | 333.98% |
| 2019 Q3 | 18.62 Million CNY | 31.26% |
| 2019 FY | 74.04 Million CNY | 54.93% |
| 2019 Q1 | 8.64 Million CNY | -27.93% |
| 2019 Q2 | 14.19 Million CNY | 64.16% |
| 2019 Q4 | 32.57 Million CNY | 74.85% |
| 2018 Q1 | 2.68 Million CNY | -89.91% |
| 2018 FY | 47.78 Million CNY | -25.12% |
| 2018 Q4 | 11.99 Million CNY | -25.82% |
| 2018 Q2 | 16.93 Million CNY | 530.49% |
| 2018 Q3 | 16.17 Million CNY | -4.51% |
| 2017 Q3 | 23.15 Million CNY | 211.66% |
| 2017 Q4 | 26.61 Million CNY | 14.94% |
| 2017 FY | 63.82 Million CNY | 97.98% |
| 2017 Q2 | 7.42 Million CNY | 32.55% |
| 2017 Q1 | 5.6 Million CNY | -60.71% |
| 2016 Q4 | 14.26 Million CNY | -4.92% |
| 2016 Q1 | 3.51 Million CNY | 124.72% |
| 2016 Q2 | -540.94 Thousand CNY | -115.38% |
| 2016 Q3 | 15 Million CNY | 2872.92% |
| 2016 FY | 32.23 Million CNY | 42.3% |
| 2015 FY | 22.65 Million CNY | -65.18% |
| 2015 Q2 | 3.51 Million CNY | -81.59% |
| 2015 Q3 | 14.28 Million CNY | 306.62% |
| 2015 Q4 | -14.22 Million CNY | -199.59% |
| 2015 Q1 | 19.08 Million CNY | 529.15% |
| 2014 Q3 | 30.3 Million CNY | 383.76% |
| 2014 Q4 | -4.44 Million CNY | -114.67% |
| 2014 Q1 | 32.94 Million CNY | -24.67% |
| 2014 Q2 | 6.26 Million CNY | -80.98% |
| 2014 FY | 65.06 Million CNY | -54.44% |
| 2013 Q3 | 40.19 Million CNY | 44.87% |
| 2013 Q1 | 31.15 Million CNY | 14.57% |
| 2013 Q4 | 43.72 Million CNY | 8.79% |
| 2013 FY | 142.81 Million CNY | 26.79% |
| 2013 Q2 | 27.74 Million CNY | -10.94% |
| 2012 Q2 | 29.49 Million CNY | 30.88% |
| 2012 Q4 | 27.18 Million CNY | -18.65% |
| 2012 Q1 | 22.53 Million CNY | -17.83% |
| 2012 FY | 112.63 Million CNY | 18.27% |
| 2012 Q3 | 33.42 Million CNY | 13.32% |
| 2011 FY | 95.24 Million CNY | 13.28% |
| 2011 Q3 | 22.13 Million CNY | -3.47% |
| 2011 Q2 | 22.92 Million CNY | 0.78% |
| 2011 Q4 | 27.42 Million CNY | 23.9% |
| 2011 Q1 | 22.75 Million CNY | 0.53% |
| 2010 FY | 84.07 Million CNY | 12.42% |
| 2010 Q1 | 17.12 Million CNY | -9.46% |
| 2010 Q2 | 25.08 Million CNY | 46.54% |
| 2010 Q3 | 19.23 Million CNY | -23.34% |
| 2010 Q4 | 22.63 Million CNY | 17.68% |
| 2009 Q3 | 21.62 Million CNY | 0.0% |
| 2009 Q4 | 18.9 Million CNY | -12.54% |
| 2009 FY | 74.78 Million CNY | 37.75% |
| 2008 FY | 54.29 Million CNY | 47.68% |
| 2007 FY | 36.76 Million CNY | 0.0% |